Pfizer’s Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
GSK wins FDA approval for long-acting asthma drug
GSK secured FDA approval for an inflammatory disease drug that it says could reach £3 billion ($4 billion) in peak sales. The agency greenlit depemokimab



